Status:
UNKNOWN
Anti COVID 19 Hyperimmune Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients
Lead Sponsor:
Dow University of Health Sciences
Collaborating Sponsors:
Higher Education Commission (Pakistan)
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Severe ill Patients will be enrolled in the study (n=310) after duly filled consent forms. Recipients will be divided into 2 group, each group contain 155 patients to compare Safety and efficacy of pa...
Detailed Description
The research team at Dow University of Health Sciences has purified immunoglobulin (both SARS-CoV 2 antibodies and existing antibodies) from convalescent plasma of COVID19 individuals and pooled it to...
Eligibility Criteria
Inclusion
- Above 18 years of age
- Have positive COVID PCR on nasopharyngeal and/or oropharyngeal swabs
- classified as severe\* COVID-19 according to WHO guideline (5L-15L of oxygen requirement on FM, NRM)
- Consent given by the patient or first degree relative
Exclusion
- Critical COVID-19 patients \[ non-invasive ventilation (HFNC, BiPAP, CPAP) and invasive ventilation\],
- Pregnant females
- Previous allergic reaction to immunoglobulin treatment
- Known case of any autoimmune disorder
- Chronic kidney disease
- Known case of thromboembolic disorder
- Aseptic meningitis
Key Trial Info
Start Date :
August 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 2 2022
Estimated Enrollment :
310 Patients enrolled
Trial Details
Trial ID
NCT04891172
Start Date
August 1 2021
End Date
December 2 2022
Last Update
October 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dow University of Health Sciences
Karachi, Sindh, Pakistan, 74200